HANNAH ALISON L.
SEC CIK 1645600 · EDGAR
BoughtSold
Most active insiders at RIGL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Ali-Jackson Kamil | Dir | — | $160.4K |
| 2 | MOOS WALTER H | Dir | — | $145.4K |
| 3 | Rojkjaer Lisa | EVP, Chief Medical Off | — | — |
| 4 | Santos David A | EVP, Chief Commercial Off | — | — |
| 5 | HANNAH ALISON L. | EVP, Chief Medical Off | — | — |
| 6 | Furey Raymond J. | EVP, GC, CCO, Corp Sec | — | — |
| 7 | Schorno Dean L | EVP, CFO | — | — |
| 8 | Frohlich Mark W | Dir | — | — |
| 9 | Wasman Jane | Dir | — | — |
| 10 | LAPOINTE ANTHONY GREGG | Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-10 21:53 | 2026-07-08 | RIGL | RIGEL PHARMACEUTICALS INC | HANNAH ALISON L. | EVP, Chief Medical Off | A - Grant | $0.00 | +24.4K | 35.0K | +230% | $0 | |
| 2026-05-19 20:49 | 2026-05-15 | RIGL | RIGEL PHARMACEUTICALS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +5,750 | 16.4K | +54% | $0 | |
| A | 2025-06-03 | 2025-06-01 | NEO | NEOGENOMICS INC | HANNAH ALISON L. | Dir | M - OptEx | $0.00 | +12.3K | 131.0K | +10% | $0 |
| D | 2025-06-03 | 2025-06-01 | NEO | NEOGENOMICS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +12.3K | 131.0K | +10% | $0 |
| D | 2025-05-28 | 2025-05-23 | RIGL | RIGEL PHARMACEUTICALS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +2,500 | 10.6K | +31% | $0 |
| D | 2024-08-13 | 2024-08-10 | NEO | NEOGENOMICS INC | HANNAH ALISON L. | Dir | M - OptEx | $0.00 | +11.3K | 118.8K | +11% | $0 |
| D | 2024-05-29 | 2024-05-25 | RIGL | RIGEL PHARMACEUTICALS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +25.0K | 81.2K | +44% | $0 |
| D | 2023-07-12 | 2023-05-26 | RIGL | RIGEL PHARMACEUTICALS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +25.0K | 56.2K | +80% | $0 |
| 2022-07-21 | 2022-07-19 | CTMX | CytomX Therapeutics, Inc. | HANNAH ALISON L. | Chief Medical Off | A - Grant | $0.00 | +15.0K | 37.5K | +67% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | CytomX Therapeutics, Inc. | HANNAH ALISON L. | Chief Medical Off | S - Sale | $1.42 | -5,602 | 31.9K | -15% | -$7,955 | |
| D | 2022-06-14 | 2022-06-10 | NEO | NEOGENOMICS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +15.6K | 107.4K | +17% | $0 |
| D | 2022-05-23 | 2022-05-20 | RIGL | RIGEL PHARMACEUTICALS INC | HANNAH ALISON L. | Dir | A - Grant | $0.00 | +25.0K | 31.2K | +400% | $0 |
| D | 2022-02-04 | 2022-02-02 | CTMX | CytomX Therapeutics, Inc. | HANNAH ALISON L. | Chief Medical Off | A - Grant | $0.00 | +22.5K | 22.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations